Last reviewed · How we verify
Intravitreous injection of ranibizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravitreous injection of ranibizumab (Intravitreous injection of ranibizumab) — José Cunha-Vaz.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravitreous injection of ranibizumab TARGET | Intravitreous injection of ranibizumab | José Cunha-Vaz | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravitreous injection of ranibizumab CI watch — RSS
- Intravitreous injection of ranibizumab CI watch — Atom
- Intravitreous injection of ranibizumab CI watch — JSON
- Intravitreous injection of ranibizumab alone — RSS
Cite this brief
Drug Landscape (2026). Intravitreous injection of ranibizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/intravitreous-injection-of-ranibizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab